PRMA Insights: The Roadmap to Pricing and Reimbursement Success
Authors of the metastatic breast cancer report
The ground-breaking metastatic breast cancer report is written by a team of industry experts and validated by payers and KOLs in every market. Our industry experts bring global hands-on experience of the strategic, commercial, technical and scientific market access challenges faced across the pharmaceutical and healthcare industries today.
 |
David Sykes David Sykes is the founding partner of PRMA Consulting. He has more than 15 years’ experience in P&R, market access, and health outcomes and has held senior leadership roles at Lilly and J&J. David has developed European and global P&R and market access programs to quantify, capture, and communicate product value, including several products launched across multiple therapy areas. David has published extensively in the area of health economics. |
| Professor Jacques Bonneterre Professor Bonneterre is a Professor of Medical Oncology and Department Head of the Centre for Breast Cancer at Oscar Lambret, one of France’s leading cancer centers. Professor Bonneterre has published widely in the field of breast cancer and was an author on the CECOG third consensus on the medical treatment of breast cancer published in the Annals of Oncology in 2009. |
Sotiria Papanicolaou |
 |
Dr Marcus Healey, MBA Marcus is the principal medical writer at PRMA Consulting and has more than 8 years’ experience in medical communications and 20 years’ experience across numerous therapeutic areas and markets. Marcus has co-authored and edited books and numerous journal articles. |
 |
Dr Jan Geldmacher Dr Geldmacher has over 30 years’ experience in the German healthcare system. He is currently a member of the drug committee of the G-BA (Federal Joint comment), the expert advisory committee on prescription-only products of the German Health Ministry, and the drug commission of the German Medical Association (AKDÄ). He also represents AKDÄ on the drug safety committee of the BfArM (Federal Institute for Drug and Medicals Device). |
 |
Shkun Chadda Shkun has more than 9 years’ experience in health outcomes, in both the pharmaceutical and consultancy sectors. She has worked in health outcomes groups at national, regional, and global levels in blue-chip pharmaceutical companies, and as the health outcomes lead on regional cross-functional teams for several oncology products. Shkun has also been responsible for multiple NICE and SMC submissions in oncology. |
 |
Dr Mark Larkin Mark has over 10 years’ experience in strategy consulting and finance. He has been involved in strategy development across a broad range of therapeutic areas, at both European and global levels, and has extensive experience of advising North American and European developers on P&R and market access strategies, for both in-house launches and to support business development objectives. |
 |
Dr Alexander (Sandy) Simpson Sandy has more than 20 years’ experience in the pharmaceutical industry; he has held senior medical positions in the UK and Europe with Eli Lilly, and has been directly involved in the launches of many compounds. Until recently he represented the Association of the British Pharmaceutical Association in the Scottish Medicines Consortium. |
| Nikos Kotsopoulos Nikos has 8 years experience in the pharmaceutical industry. He was responsible for P&R and market access at GlaxoSmithKline in Greece, where he was also involved in several regional market access teams. Nikos has been involved in the development of health outcomes strategies for several therapeutic areas as part of the Global Health Outcomes group. He has substantial experience in the design and implementation of PRO &and health economic studies and multinational Phase 2 and 3 clinical trials. |
| Vanessa Mirsky Our in-house US expert, Vanessa has more than 10 years’ consultancy experience in healthcare and life sciences commercialization strategy, with a strong background in managed markets, including reimbursement dynamics among public and private payors in the US. Vanessa has worked with multinational pharmaceutical companies and small boutique firms in the US, and has significant experience in oncology and biologics. |
 |
Steve Crowley Steve has more than 20 years’ experience in P&R and market access with leading pharmaceutical companies, including GlaxoWellcome, Merck, and Janssen-Cilag. He has considerable experience of the Asia Pacific market and of building market access capabilities across this region. Steve has an in-depth understanding of the Japanese healthcare system and associated market access challenges. |
| Dr Luis Prieto Luis has held positions as senior health economist in Spain and Portugal and senior health outcomes manager at a leading pharmaceutical company. Luis has significant experience of leading P&R submissions in Spain and working with the Regions to achieve market access across a range of therapy areas. |
Find out more about the metastatic breast cancer report:
The report delivers Scope of the report Authors of the reportprmainsights